Lead Sponsor

University of Göttingen

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•all risk groups in international prognostic index
•diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph node or by sufficiently extensive biopsy of an extranodal involvment, if there is no lymph node involvment.
•these lymphomas comprise: peripheral T-cell lymphoma PTCL-NOS Lennert´s lymphoma T-zone lymphoma angioimmunoblastic T-cell-lymphoma
•Performance status: ECOG (Eastern Cooperative Oncology Group Score) 0-3(Karnofsky index 40-100%)
•written consent of the patient
•Declaration of center participation

•Already initiated lymphoma therapy(exept for the prephase treatment specified for this study)
•Serious accompanying disorder or impaired organ function
•bone marrow involvement\>25%
•Known hypersensitivity to medications to be used
•Know HIV-positivity
•Active hepatitis infection, active CMV infection, prior florid tuberculosis
•floride systemic infections
•suspicion that patient compliance will be poor
•Simultaneous participation in any the study protocol
•prior chemo-or radiotherapy for malignancy
•other concomitant malignant disease
•Pregnancy or lactation period

Related studies

NCT03922724 · Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, and more

NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more

NCT06561048 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, and more

NCT06909877 · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

NCT07283822 · Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, and more

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma